Wells Fargo Maintains Gilead at Overweight, Raises Target to $190
Wells Fargo maintained its Overweight rating on Gilead Sciences and raised its price target to $190 from $165.
Wells Fargo maintained its Overweight rating on Gilead Sciences and raised its price target to $190 from $165.